Milestone Pharmaceuticals Inc. (MIST) intrinsic value & 10-year financials
Milestone Pharmaceuticals Inc. (MIST) has a Graham intrinsic value of $50.59 per share. At $0.71 on Oct 17, 2026, the stock trades 99% below that value. Over the last 9 fiscal years revenue shrank 43.3% a year to $1.5M, with an average return on invested capital of 42.4%.
- Graham intrinsic value
- $50.59
- Share price (Oct 17, 2026)
- $0.71
- Price vs Graham value
- 99% below
- Market cap
- $59.5M
- Revenue (FY2025)
- $1.5M
- Revenue growth (9-yr CAGR)
- -43.3%
- ROIC (10-yr avg)
- 42.4%
- Free cash flow (FY2025)
- -$49.3M
MIST 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.5M | -$63.1M | -$0.75 | -$49.3M | -4019.4% | -184.1% |
| FY2024 | $0 | -$41.5M | -$0.67 | -$28.9M | — | -86.2% |
| FY2023 | $1.0M | -$59.7M | -$1.39 | -$46.5M | -6109.8% | -103.8% |
| FY2022 | $5.0M | -$58.4M | -$1.38 | -$52.7M | -1192.8% | -195.8% |
| FY2021 | $15.0M | -$42.9M | -$1.02 | — | -287.2% | -121.7% |
| FY2020 | — | -$50.0M | -$1.70 | — | — | -151.8% |
| FY2019 | — | -$55.2M | — | -$51.6M | — | 1225.8% |
| FY2018 | — | -$23.2M | — | -$21.1M | — | -43.5% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Milestone Pharmaceuticals Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Milestone Pharmaceuticals Inc. has historically struggled to out-earn its cost of capital, averaging just -43.5% ROIC.
Milestone Pharmaceuticals Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Milestone Pharmaceuticals Inc. is modeled at -43.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $50.59 per share.